September 2016. The USPTO issued a Notice of Allowance for a patent application protecting the company's technology platform.
September 2016. The EPO granted a European Patent for the company's application dealing with suppression of cardiovascular side effects in melanocortin analogs intended for therapeutic and related uses.
September 2016. Tensive Controls was awarded a $2.3 million grant from the National Cancer Institute to further advance research and development of a melanocortin-based therapeutic for cancer cachexia.
June 2016. Tensive Controls completed a $1.7 million financing round through Centennial Investors Angel Investor Network. Funds will be used to advance the development of applications of the company's technology platform for modifying peptides with applications in human and animal health.
June 2017. Tensive Controls demonstrated progress toward development path milestones and successfully transitioned to Phase 2 of the National Cancer Institute Grant.